There is also an oral GLP-1 RA peptide called MET-002, a product of Metsera’s platform for optimizing the oral delivery of ...

Metsera has raised over $500 million to date. Highly competitive, clinical-stage portfolio accelerating Phase 2 trials of ultra-long acting, fully-biased injectable GLP-1 RA underway Metsera recently ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

initiated an SGLT-2 inhibitor or glucagon-like peptide-1 receptor agonist (GLP-1 RA), with a dipeptidyl peptidase-4 (DPP-4) ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...